Infect Chemother.  2009 Oct;41(5):259-264. 10.3947/ic.2009.41.5.259.

Vaccine Strategy for Influenza A (H1N1) Pandemic

• Choi WS
• Kim WJ

• KMID: 1473650
• DOI: http://doi.org/10.3947/ic.2009.41.5.259

Abstract

Four months have passed since the World Health Organization declared worldwide pandemic by the novel influenza A (H1N1) virus, but the incidence rate does not seem to dwindle and each day we are faced with news from all around the world on death by this troublesome virus. Pandemic influenza vaccine is considered one of the most effective countermeasures for protecting susceptible individuals. However, it is envisaged that production of sufficient vaccine within an ideal timeframe will not be feasible, and thus, vaccine supply is expected to fall short of demand. Therefore, it is mandatory to establish a proper vaccine strategy for maximizing the effect of pandemic influenza vaccine. In this article, we have described many critical points that should be taken into consideration when establishing pandemic vaccine strategies based on the newest data and the strategies adopted by other countries.

Keyword

Influenza; Vaccine; Strategy; Pandemic

MeSH Terms

Incidence
Influenza Vaccines
Influenza, Human
Pandemics
Viruses
World Health Organization
Influenza Vaccines

Reference

1. World Health Organization [Internet]. cited 2009 Sep 29. Available from: URL: http://www.who.int/csr/disease/swineflu/frequently_asked_questions/levels_pandemic_alert/en/index.html.

2. World Health Organization [Internet]. cited 2009 Sep 29. Available from: URL: http://www.who.int/csr/don/2009_09_18/en/index.html.

3. Pandemic (H1N1) 2009 briefing note 1 Viruses resistant to oseltamivir (Tamiflu) identified. Wkly Epidemiol Rec. 2009. 84:299–399.

4. Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep. 2009. 58:893–896.

5. Duwe S, Heider A, Braun C, Schweiger B, Buchholz U. Person-to-person transmission of oseltamivir-resistant influenza A/H1N1 viruses in two households; Germany 2007/08. J Clin Virol. 2009. 46:295–297.

6. Leung TW, Tai AL, Cheng PK, Kong MS, Lim W. Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong. J Clin Virol. 2009. 46:298–299.

7. Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009. MMWR Morb Mortal Wkly Rep. 2009. 58:969–972.

8. Collin N, de Radiguès X. World Health Organization H1N1 Vaccine Task Force. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Vaccine. 2009. 27:5184–5186.

9. World Health Organization [Internet]. cited 2009 Sep 29. Available from: URL: http://www.who.int/csr/disease/swineflu/notes/pandemic_influenza_vaccines_20090924/en/index.html.

10. Medical Countermeasures.gov [Internet]. cited 2009 Sep 29. U.S. Department of Health & Human Services;Available from: URL: https://www.medicalcountermeasures.gov/BARDA/MCM/panflu/factsheet.aspx.

11. Department of Health [Internet]. cited 2009 Sep 29. Available from: URL: http://nds.coi.gov.uk/clientmicrosite/Content/Detail.aspx?ClientId=46&NewsAreaId=2&ReleaseID=405829&SubjectId=36.

12. Xinhuanet [Internet]. cited 2009 Sep 29. Xinhua News Agency;Available from: URL: http://news.xinhuanet.com/english/2009-08/21/content_11924173.htm.

13. YOMIURI ONLINE [Internet]. The Daily Yomiuri;Available from: URL: http://www.yomiuri.co.jp/dy/national/20090828TDY01303.htm.

14. Korea Centers for Disease Control and Prevention [Internet]. cited 2009 Sep 29. Available from: URL: http://www.cdc.go.kr/kcdchome/jsp/home/common/brd/COMMBRD0200Detail.jsp?boardid=1002&boardseq=22105&menuid=100039&appid=kcdchome&contentid=null&pageNum=2&tabinx=1&pageNo=&q_value=%EC%8B%A0%EC%A2%85%EC%9D%B8%ED%94%8C%EB%A3%A8%EC%97%94%EC%9E%90%20%EB%B0%B1%EC%8B%A0&q_name=&sub=1&q_value=%EC%8B%A0%EC%A2%85%EC%9D%B8%ED%94%8C%EB%A3%A8%EC%97%94%EC%9E%90%20%EB%B0%B1%EC%8B%A0.

15. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009. 58:1–8.

16. European Centre for Disease Prevention and Control. ECDC Interim guidance: use of specific pandemic influenza vaccines during the H1N1 2009 pandemic [Internet]. 2009. Aug. cited 2009 Sep 29. Stockholm: European Centre for Disease Prevention and Control;Available from: URL: http://ecdc.europa.eu/en/publications/Publications/0908_GUI_Pandemic_Influenza_Vaccines_during_the_H1N1_2009_Pandemic.pdf.

17. World Health Organization [Internet]. cited 2009 Sep 29. Available from: URL: http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090806/en/index.html.

18. European Medicines Agency [Internet]. cited 2009 Sep 29. Available from: URL: http://www.emea.europa.eu/influenza/vaccines/home.htm.

19. Xinhuanet [Internet]. cited 2009 Sep 29. Xinhua News Agency;Available from: URL: http://news.xinhuanet.com/english/2009-09/21/content_12091778.htm.

20. Mylius SD, Hagenaars TJ, Lugnér AK, Wallinga J. Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. Vaccine. 2008. 26:3742–3749.

21. Korea Centers for Disease Control and Prevention [Internet]. cited 2009 Sep 29. Available from: URL: http://www.cdc.go.kr/kcdchome/jsp/home/common/brd/COMMBRD0200Detail.jsp?boardid=1002&boardseq=22134&menuid=100039&appid=kcdchome&contentid=null&pageNum=2&tabinx=1&pageNo=&q_value=&q_name=&sub=1.

22. World Health Organization [Internet]. cited 2009 Sep 29. Available from: URL: http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090713/en/index.html.

23. Centers for Disease Control and Prevention [Internet]. cited 2009 Sep 29. Available from: URL: http://www.cdc.gov/media/pressrel/2009/r090729b.htm.

24. El Sahly HM, Keitel WA. Pandemic H5N1 influenza vaccine development: an update. Expert Rev Vaccines. 2008. 7:241–247.

25. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL. Response after One Dose of a Monovalent Influenza A (H1N1) 2009 Vaccine--Preliminary Report. N Engl J Med. 2009.

26. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. Trial of Influenza A (H1N1) 2009 Monovalent MF59-Adjuvanted Vaccine--Preliminary Report. N Engl J Med. 2009.

27. National Institute of Allergy and Infectious Diseases [Internet]. cited 2009 Sep 29. Available from: URL: http://www3.niaid.nih.gov/news/newsreleases/2009/H1N1PedTrial.htm.

28. Reuters [Internet]. cited 2009 Sep 29. Thomson Reuters;Available from: URL: http://www.reuters.com/article/marketsNews/idUSLI54489920090818.

29. Evans D, Cauchemez S, Hayden FG. "Prepandemic" immunization for novel influenza viruses, "swine flu" vaccine, Guillain-Barré syndrome, and the detection of rare severe adverse events. J Infect Dis. 2009. 200:321–328.

30. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, Clark S, Haber P, Stolley PD, Schonberger LB, Chen RT. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998. 339:1797–1802.

31. Centers for Disease Control and Prevention [Internet]. cited 2009 Sep 29. Available from: URL: http://www.cdc.gov/h1n1flu/vaccination/safety_planning.htm.